Cambridge researchers have developed miniature brain-and-spinal-cord organoid systems that can reverse nerve damage previously considered irreversible [1, 2].
This breakthrough suggests that the biological ability to regrow neurons, which is typically lost after early development, can be reactivated. If translated to clinical use, this could provide a pathway to treat permanent spinal cord injuries and other degenerative neurological conditions.
The team in Cambridge, United Kingdom, created these organoid systems to mimic the connection between the brain and the spinal cord [1, 2]. These lab-grown models are capable of transmitting signals and triggering tiny muscle contractions, providing a controlled environment to study how neurons behave after injury [1, 2].
During the study, researchers identified a specific gene network that controls the regenerative capacity of neurons [1, 2]. They discovered that while neurons lose their innate ability to regrow after developmental damage, this function can be switched back on [1, 2].
To achieve this reactivation, the scientists utilized an existing hormone drug alongside the targeting of the identified gene network [1, 2]. This combination successfully boosted the regeneration of nerve fibers within the organoid models [1, 2].
The study was reported on May 28, 2026 [1]. By using human organoids, the researchers were able to observe the precise mechanisms that prevent nerve regrowth in humans, a process that has long been a barrier in regenerative medicine [1, 2].
“Miniature brain-and-spinal-cord organoid systems can transmit signals and trigger tiny muscle contractions.”
The discovery shifts the understanding of nerve damage from a permanent state to a reversible one by identifying the genetic 'switch' for regrowth. By utilizing an existing hormone drug, the research suggests that the tools for treatment may already exist, though the transition from lab-grown organoids to living human patients remains a significant medical hurdle.
